^
    Back
    Association details:
    Biomarker:GNAQ mutation
    Cancer:Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    1906PBasal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial

    Excerpt:
    Higher NKG2D was reported on CD3-CD56dim cells from OR patients as compared to PD patients (p = 0.0054).
    DOI:
    10.1093/annonc/mdz268.033